• India is one of key markets for research, manufacturing and supplying pharmaceuticals APIs. With the changing mainstream in pharmaceutical industry, Indian players are actively exploring global opportunities. The global APIs market is expanding at a remarkable pace. It is estimated to witness a CAGR of 6.3% over 2016-21 valuing at US$ 214 billion in 2021. The global veterinary APIs are further expected to gain market value of US$ 9.2 billion in 2025 as against US$ 5.2 billion in 2017. Increasing requirement of high-quality additives, vaccines and hygiene management products, coupled with adoption of pets and awareness relating to their health shall accelerate the demand for veterinary APIs products globally.
  • We understand that the single most important commitment we make is to advance animal health. By doing so, we help protect and enhance public health as well. Our endeavours towards creating a value-centric growth are clearly driven by our passionate R&D and innovation to meet customer needs.
  • We move ahead with a positive intent of unleashing the industry potential with an uncompromised focus on highquality and cost-effective products for our customers. We are also planning to explore opportunities in the poultry API segment as a part of our market expansion strategy. As an endeavour of continuous progress, we have the wellthought out strategies in place for increasing shareholders’ value and creating long-term sustainability.
  • The global Animal Health pharmaceutical market was valued at about US$ 30 billion in 2016 and is expected to grow over US$ 45 billion in 2025 at 5% CAGR. Out of this, 60% accounts for livestock animals and 40% goes in for the companion animal segment.
  • The global Animal Health pharmaceutical market was valued at about US$ 30 billion in 2016 and is expected to grow over US$ 45 billion in 2025 at 5% CAGR. Out of this, 60% accounts for livestock animals and 40% goes in for the companion animal segment.
  • Our Animal Health portfolio will increase by covering more species and therapeutic categories. The increasing poultry consumption and pet pesticides have led us to make newer products in the Codccidiostat, Parasiticides and Anti-Infective categories.
  • Our cost-effective quality products make our customers stick to us for a longer period for their repeated requirements. <1% customer attrition over the past 20 years.
  • R&D is the backbone of our Company with a team of more than 30 competent and qualiͤ ed people. It drives all the integral activities, right from new product development and efͤ cient process development to exploring newer markets through our two centres. Our dedicated team works relentlessly to develop environment-friendly processes for newer as well as existing APIs
  • The growth outlook is positive, with the GDP to grow at 7% in 2019-20 on account of lower repo rates, sustained resolution of stressed assets, better governance of public sector banks and a reform-focused policy framework. However, the growth will depend on the economy’s ability to consolidate its fiscal debt, expand and utilise capacities, create jobs and promote private investment in tandem with consumption.
  • India accounts for 18% of the global livestock population and ranked as the largest producer of cattle, chicken and fish. The increasing awareness about animal health is the predominant element for the rising demand of animal healthcare products in India.
  • China is expected to witness at 10% CAGR over 2018-24. The increasing awareness and knowledge among the pet owners about pet disease, the favourable Government initiatives for pet keeping and advancement in new product development are the key factors improving the growth in this region.

My view: This is one of the companies you should buy and forget, it operates in a space where opportunity size is huge plus has a clean management which has delivered in the post. Deserves a SMALL allocation in portfolio.

 

Leave a Reply

Your email address will not be published. Required fields are marked *